Jiang D, Chen L, Huang J, Wang H, Song Q, Shi P, Wang H, Hou Y. Mouse double minute 2 amplification in oesophageal squamous cell carcinoma is associated with better outcome.
Histopathology 2020;
77:963-973. [PMID:
32652667 DOI:
10.1111/his.14208]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2020] [Accepted: 07/07/2020] [Indexed: 12/29/2022]
Abstract
AIMS
This study aimed to determine the frequency of mouse double minute 2 (MDM2) amplification in oesophageal squamous cell carcinomas (ESCC) and to clarify its prognostic significance.
METHODS AND RESULTS
We investigated MDM2 amplification on tissue microarrays using fluorescence in-situ hybridisation and analysed its correlations with clinicopathological features and outcomes in 515 Chinese ESCC patients. MDM2 amplifications were found in 37 of 515 ESCC patients (7.2%). They were significantly negatively correlated with tumour size (PÂ =Â 0.045), disease progression (PÂ =Â 0.002) and death (PÂ =Â 0.003). Univariate analysis showed that the following clinicopathological factors were associated with disease-free survival (DFS) and overall survival (OS): differentiation (PÂ =Â 0.025 for DFS and PÂ =Â 0.061 for OS), vessel invasion (PÂ =Â 0.001 and PÂ =Â 0.002), nerve invasion (PÂ =Â 0.009 and PÂ =Â 0.001), clinical stage (PÂ <Â 0.001 and PÂ <Â 0.001) and MDM2 amplification (PÂ =Â 0.012 and PÂ =Â 0.014). Multivariate Cox regression analysis showed that MDM2 amplification was an independent prognostic factor for improved outcomes (PÂ =Â 0.023 for DFS, PÂ =Â 0.027 for OS) and the clinical stage was an independent prognostic factor for poor outcomes (PÂ <Â 0.001). When survival analyses were conducted at different clinical stages, MDM2 amplification was associated with longer DFS and OS in stages I-II ESCC (PÂ =Â 0.003 for DFS and PÂ =Â 0.003 for OS), but there was no significant survival difference in stages III-IVa ESCC.
CONCLUSIONS
MDM2 amplification was significantly correlated with an improved patient outcome, especially in stage I and II disease, and was verified as an independent prognostic factor in our patients. Therefore, MDM2 amplification may be a potential biomarker for risk stratification of the lower stages of ESCC.
Collapse